Loading...
A dose-limiting effect of vincristine, which is used effectively in the treatment of acute lymphoblastic leukemia (ALL), is peripheral neuropathy. To identify potential genetic variants associated with vincristine-induced peripheral neuropathy, investigators performed a genome-wide association study involving 222 children with newly diagnosed ALL and 99 children with relapsed ALL. All patients received vincristine-based treatment and underwent physical examinations for neuropathy.
A single-nucleotide polymorphism (SNP) in the promoter region of the CEP72 gene was associated with peripheral neuropathy. The CEP72 TT genotype occurred in 16% of the study population and was associated with decreased expression of CEP72 messenger RNA. More patien…